MARKET NEWS

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
First US Patients With Persistent Cardiac Arrythmias Treated Using Volta Medical’s Artificial Intelligence-Based Analysis
Certara Announces FDA Renewal & Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Intra-Cellular Therapies Announces US FDA Approval of CAPLYTA for the Treatment of Bipolar Depression in Adults
Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
Oral Splicing Modifiers That Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Intertek’s Pharmaceutical Services laboratory in Whitehouse, NJ, is an FDA- and DEA-registered cGMP-compliant facility, specializing in complex and routine services to support the development of drug products, formulations, medical devices, and drug delivery systems for clients globally. We have pharmaceutical expertise for various GMP and CMC testing, including method development and validation, stability, extractables and leachables, and elemental impurities. Partnering with our Whitehouse facility brings the assurance, confidence, and peace of mind that comes with collaborating with a current good manufacturing practice (cGMP) compliant facility, ensuring that testing will be carried out to the most up-to-date and highest quality standards, preserving the integrity of your products. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics

Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

Heat Biologics, Inc. recently announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM (obiltoxaximab) Injection,….

TFF Pharmaceuticals Announces Final Data From Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

TFF Pharmaceuticals Announces Final Data From Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

TFF Pharmaceuticals, Inc. recently announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study (NCT #04576325) of Inhaled Voriconazole Powder (TFF VORI) in asthma patients….

PharmaTher Enters Process Development Agreement Eith LTS for Ketamine Microneedle Patch

PharmaTher Enters Process Development Agreement Eith LTS for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. and LTS LOHMANN Therapie-Systeme AG recently announced they have entered into a process development agreement for the clinical trial scale up of PharmaTher’s proprietary….

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

Chord Therapeutics recently announced it is being acquired by Merck; the strategic acquisition enables Merck to expand its neurology pipeline to develop Chord’s lead drug….

Kenox Pharmaceuticals Announces Successful Completion of a Pre-IND Meeting With US-FDA for Novel Inhaled Drug-Device Combination Product 

Kenox Pharmaceuticals Announces Successful Completion of a Pre-IND Meeting With US-FDA for Novel Inhaled Drug-Device Combination Product 

Kenox Pharmaceuticals Inc. has submitted Type B Pre-Investigational New Drug (IND) meeting request with the US FDA for its lead program KNX018, a novel inhaled drug-device combination product as an….

Novartis Strengthens Immunotherapy Pipeline With Option, Collaboration & License Agreement With BeiGene

Novartis Strengthens Immunotherapy Pipeline With Option, Collaboration & License Agreement With BeiGene

Novartis recently announced the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 12 – Excipients
January 19 – Drug Delivery